Last 29 quarters of trend data · Healthcare · Vaccines & Infectious Disease
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -0.21 | — | — | — | — | — | — | 0.42 | — | — | 2.70 | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 0.24 | 5.13 | 0.54 | 6.83 | 143.16 | 34.29 | 19.33 | 57.76 | 99.47 | 10.70 | 12.92 | 96.72 | 38.50 | 62.71 | 38.09 | 86.08 | 72.12 | 71.60 | 87.37 | 222.19 | 8559.25 |
| — | -85.0% | -97.2% | -88.2% | +43.9% | +220.4% | +49.7% | -40.3% | +158.4% | -82.9% | -66.1% | +12.4% | -46.6% | -12.4% | -56.4% | -61.3% | -99.2% | -97.3% | -97.2% | -96.2% | — | |
| P/B Ratio | 0.24 | 5.21 | 1.89 | 2.43 | 1.81 | 1.41 | 0.73 | 0.62 | — | 1.08 | 0.82 | 6.38 | 4.48 | 14.82 | 15.07 | 11.06 | 9.82 | 9.64 | 9.42 | 14.95 | 68.02 |
| — | +268.3% | +157.6% | +294.0% | — | +30.5% | -10.2% | -90.3% | — | -92.7% | -94.6% | -42.3% | -54.3% | +53.8% | +59.9% | -26.0% | -85.6% | -87.3% | -91.7% | -86.3% | -31.2% | |
| P/FCF | — | 11.12 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | 6.37 | — | — | — | — | 0.03 | — | — | 0.93 | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 57.5% | 100.0% | 100.0% | 100.0% | -52.1% | 100.0% | 73.2% | 100.0% | 100.0% | 100.0% | 42.5% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| — | 0.0% | +36.7% | 0.0% | -152.1% | 0.0% | +72.1% | 0.0% | 0.0% | 0.0% | -57.5% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | |
| Operating Margin | -4024.9% | -763.0% | -6.8% | -951.6% | -12907.7% | -3827.4% | -1924.0% | -6187.5% | -3269.2% | -1586.4% | -2489.5% | -2235.9% | -969.7% | -588.8% | -278.0% | -878.4% | -641.3% | -461.5% | -552.2% | -1383.0% | -10340.1% |
| — | +80.1% | +99.6% | +84.6% | -294.8% | -141.3% | +22.7% | -176.7% | -237.1% | -169.4% | -795.6% | -154.6% | -51.2% | -27.6% | +49.7% | +36.5% | +93.8% | +78.6% | +71.1% | +54.6% | — | |
| Net Margin | -1106.7% | -761.9% | -5.4% | -814.1% | -11763.9% | -4256.0% | -1643.8% | 13854.7% | -13060.4% | -1517.7% | 477.0% | -3535.8% | -1040.4% | -557.0% | -272.9% | -843.0% | -618.8% | -453.5% | -539.5% | -1385.3% | -10276.3% |
| — | +82.1% | +99.7% | -105.9% | +9.9% | -180.4% | -444.6% | +491.8% | -1155.4% | -172.5% | +274.8% | -319.4% | -68.1% | -22.8% | +49.4% | +39.1% | +94.0% | +79.0% | +72.0% | +54.4% | — |
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -196.9% | -101.2% | -4.7% | -54.0% | -31.7% | -36.3% | -14.5% | 98.5% | -777.8% | -32.8% | 8.0% | -45.9% | -38.0% | -29.0% | -24.3% | -24.3% | -19.4% | -14.4% | -13.7% | -21.1% | -18.8% |
| — | -178.8% | +67.5% | -154.8% | +95.9% | -10.6% | -282.4% | +314.6% | -1948.3% | -13.2% | +132.7% | -88.6% | -96.0% | -101.6% | -77.1% | -15.3% | -3.2% | +16.2% | +16.1% | -58.3% | +77.3% | |
| ROA | -30.5% | -38.5% | -2.3% | -29.9% | -19.9% | -25.8% | -11.1% | 39.0% | -103.6% | -19.5% | 4.3% | -25.0% | -23.5% | -18.8% | -16.5% | -17.1% | -14.1% | -10.7% | -10.1% | -16.0% | -15.1% |
| — | -49.3% | +79.3% | -176.6% | +80.8% | -32.1% | -360.0% | +256.4% | -341.0% | -3.9% | +125.9% | -45.9% | -66.8% | -74.9% | -62.7% | -7.1% | +6.9% | +23.0% | +24.1% | -44.3% | +21.4% | |
| ROIC | -163.0% | — | -25.8% | -87.1% | -42.9% | -33.8% | -19.8% | -28.5% | — | -54.0% | -50.7% | -242.4% | — | — | -309.9% | -67.5% | -40.6% | -22.2% | -21.5% | -71.0% | -2752.5% |
| — | — | -30.2% | -205.1% | — | +37.5% | +61.0% | +88.2% | — | — | +83.6% | -259.2% | — | — | -1338.0% | +5.0% | +98.5% | — | +99.3% | +65.2% | -1255.5% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.10 | 1.05 | 0.11 | 0.14 | 0.10 | 0.08 | 0.07 | 0.07 | — | 0.18 | 0.15 | 0.18 | 0.12 | 0.21 | 0.18 | 0.14 | 0.12 | 0.11 | 0.10 | 0.09 | 0.08 |
| — | +1146.6% | +62.8% | +102.5% | — | -53.7% | -53.9% | -61.4% | — | -15.1% | -17.9% | +24.2% | -0.0% | +101.0% | +81.7% | +50.1% | +54.7% | +86.6% | +32.2% | +42.6% | +32.4% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 3.90 | 1.77 | 2.19 | 2.56 | 3.90 | 4.70 | 6.31 | 7.56 | 2.86 | 3.81 | 4.23 | 6.25 | 5.90 | 3.32 | 3.46 | 3.90 | 4.03 | 4.91 | 5.30 | 4.72 | 5.25 |
| — | -62.4% | -65.3% | -66.2% | +36.5% | +23.5% | +49.4% | +20.9% | -51.6% | +14.7% | +22.1% | +60.5% | +46.4% | -32.4% | -34.7% | -17.4% | -23.2% | -31.3% | -18.9% | -45.9% | -36.5% | |
| Quick Ratio | 3.90 | 1.77 | 2.19 | 2.56 | 3.90 | 4.70 | 6.31 | 7.56 | 2.86 | 3.81 | 4.23 | 6.25 | 5.90 | 3.32 | 3.46 | 3.90 | 4.03 | 4.91 | 5.30 | 4.72 | 5.25 |
| — | -62.4% | -65.3% | -66.2% | +36.5% | +23.5% | +49.4% | +20.9% | -51.6% | +14.7% | +22.1% | +60.5% | +46.4% | -32.4% | -34.7% | -17.4% | -23.2% | -31.3% | -18.9% | -45.9% | -36.5% | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 29 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying ALGS stock.
Aligos Therapeutics, Inc.'s current P/E is -0.2x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Aligos Therapeutics, Inc.'s current operating margin is -4024.9%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Aligos Therapeutics, Inc.'s business trajectory between earnings reports.